Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class ...

SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co (“Merck” or th ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

Merck & Co.'s first trial over the safety of its blockbuster cancer vaccine Gardasil was postponed mid-trial due to concerns that jurors might be influenced by media coverage surrounding the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

By Dan Levine, Mike Spector (Reuters) -Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other expensive stocks. We previously covered the 10 cheapest stocks insiders are buying recently.